我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

氨氯地平加替米沙坦对轻、中度高血压的疗效及与AVP和NO的关系

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2009年第3期
页码:
362-366
栏目:
临床研究
出版日期:
2009-05-15

文章信息/Info

Title:
Effects of amlodipine plus telmisartan on mild to moderate hypertension and their relationship to plasma AVP and NO
作者:
艾永飞1; 赵连友1; 章燕2; 薛玉生1; 赵小燕1; 侯小玲1; 景晓娟1
第四军医大学：1.唐都医院心脏内科，陕西 西安 710038； 2.生物医学工程系医学电子工程学教研室，陕西 西安 710032
Author(s):
AI Yong-fei1;  ZHAO Lian-you1;  ZHANG Yan2;  XUE Yu-sheng1;  ZHAO Xiao-yan1;  HOU Xiao-ling1;  JING Xiao-juan1
1.Department of Cardiology, Tangdu Hospital, Xi’an 710038, Shaanxi, China, 2.Department of Biomedical Engineering, Faculty of Biomedical Engineering, Fourth Military Medical University, Xi’an 710032, Shaanxi, China
关键词:
高血压; 血管加压素; 一氧化氮; 氨氯地平; 替米沙坦
Keywords:
hypertension;  arginine vasopressin;  nitric oxide;  amlodipine;  telmisartan
分类号:
R544.1
DOI:
-
文献标识码:
A
摘要:
目的 观察氨氯地平加替米沙坦对轻、中度高血压的疗效，探讨高血压患者血管加压素(AVP)和一氧化氮（NO）的变化与疗效的关系。方法 将60例轻、中度高血压病患者（包括：正在服用降压药的高血压病患者和新发病例没有服用降压药的患者）随机分为：氨氯地平组，替米沙坦组和氨氯地平＋替米沙坦组（氨+替组）,每组各20例。测定各组治疗前后血压的变化。采用放免法、比色法测定各组患者治疗前后血浆AVP和NO的含量。结果 ①氨氯地平组、替米沙坦组及氨＋替组治疗前收缩压（SBP）分别为：(146.31±3.15)mmHg、(145.92±2.71)mmHg及(146.00±2.42)mmHg；舒张压(DBP)分别为：(93.77±2.39)mmHg、(92.54±2.68)mmHg及(94.93±1.15)mmHg。在治疗6个月后，SBP分别为：(126.69±1.74)mmHg、(126.08±1.52)mmHg及(102.71±2.20)mmHg；DBP分别为：(80.76±1.13)mmHg、(81.00±0.80)mmHg和(76.11±1.36)mmHg，与治疗前比较明显降低（P<0.05）。氨+替组患者的SBP和DBP均明显低于氨氯地平组和替米沙坦组（P<0.05）；氨氯地平组与替米沙坦组比较无显著差异。②治疗1月、2月末，氨+替组患者的血压达标率均明显高于氨氯地平组和替米沙坦组（P<0.05）；氨氯地平组和替米沙坦组比较无显著差异。③氨氯地平组、替米沙坦组及氨＋替组治疗前血浆NO的含量分别为：(12.77±0.23)μmol/L、(11.68±0.35)μmol/L及(10.09±1.04)μmol/L；治疗6个月后其含量分别为：(18.50±2.14)μmol/L、(19.07±1.96)μmol/L及(25.47±1.84)μmol/L，与治疗前比较差异显著（P<0.05）。氨+替组患者NO的含量明显高于氨氯地平组和替米沙坦组（P<0.05）；氨氯地平组和替米沙坦组比较无显著差异。④氨氯地平组、替米沙坦组及氨＋替组患者治疗前血浆AVP的含量分别为：(34.71±4.36)ng/L、(33.07±3.77)ng/L及(35.06±4.12)ng/L；治疗6个月后分别为：(22.35±2.71)ng/L、(24.12±3.11)ng/L及(17.98±1.79)ng/L,与治疗前比较差异显著（P<0.05）。氨+替组血浆AVP的含量低于氨氯地平组和替米沙坦组（P<0.05），氨氯地平组和替米沙坦组组间比较无显著差异。结论 ①3个组均能有效控制血压，但氨+替组的降压效果更佳。②3个组在显著降低血压的同时，均伴有血浆AVP含量降低和血浆NO含量增高，氨+替组的效果更明显，提示AVP和NO参与了高血压的发生发展，可作为观察高血压疗效的指标。
Abstract:
AIM To observe the effect of amlodipine plus telmisartan on mild to moderate hypertension and to explore the changes of arginine vasopressin (AVP) and nitric oxide (NO) and their relationship to the therapeutic results in patients with essential hypertension. METHODS Sixty cases of mild to moderate hypertensive patients were randomly divided into: amlodipine group, telmisartan group and amlodipine+telmisartan group (n=20, each). Blood pressure was measured, and plasma AVP and NO were measured by RIA and colorimetric method before and after treatment. RESULTS After six months’ treatment, systolic blood pressure (SBP) and diastolic blood pressure (DBP) in the three groups decreased significantly (P<0.05). SBP and DBP in amlodipine+telmisartan group were lower than those in amlodipine group and telmisartan group (P<0.05), but no significant difference was observed between amlodipine group and telmisartan group. After one and two months’ treatment, the rate of well-controlled blood pressure in amlodipine+telmisartan group was higher than that in amlodipine or telmisartan group (P<0.05), and no significant difference was observed between amlodipine group and telmisartan group. After six months’ treatment, the plasma NO content increased significantly in the three groups (P<0.05). The plasma NO content in amlodipine+telmisartan group was significantly higher than that in amlodipine group or telmisartan group (P<0.05), with no significant difference between the latter two groups. The plasma AVP content decreased significantly in the three groups (P<0.05). The plasma AVP in amlodipine+telmisartan group was significantly lower than that in amlodipine group or telmisartan group (P<0.05), with no significant difference between the latter two groups. CONCLUSION Though single administration of amlodipine or telmisartan well controls blood pressure, amlodipine combined with telmisartan achieves better results. The decrease of plasma AVP content and the increase of NO content during the drug administration suggest that AVP and NO may participate in the occurrence and development of hypertension. Thus both of them can serve as indicators for curative effects.

参考文献/References

[1］ Moncrieff J, Lindsay MM, Dunn FG. Hypertensive heart disease and fibrosis［J］. Curr Opin Cardiol, 2004, 19(4):326-331.

［2］ Festa A, D’Agostino, Howard G, et al. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The insulin resistance atherosclero-sis study［J］. Kidny Int, 2000, 58(4):1703-1710.

［3］ Tsioufis C, Dimitriadis K, Chatzis D, et al. Relation of microalbuminutia to adiponectin an d augmented C-reactive protein levels in men with essential hypertension［J］. Am J Cardiol, 2005, 96(7):946-951.

［4］ Wang TJ, Evans JC, Meigs JB, et al. Low-grade albuminuriaandthe risks of hypertension and blood pressure progression［J］. Circulation, 2005, 111(11):1370-1376.

［5］ 孙宁玲,喜扬,荆珊,等. 苯磺酸氨氯地平的时间药理学对纠正老年非杓型高血压的作用［J］. 中国高血压杂志, 2007, 15(1):26-29.

［6］ 于海波,韩雅玲,王祖禄,等. 替米沙坦降压疗效的临床研究［J］. 中国高血压杂志, 2004, 12(6):515-518.

［7］ Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)［J］. J Hypertens, 2007, 25(5):1105-1187.

［8］ 王文，张宇清，马丽媛，等. CHIEF：中国高血压干预效果研究——初始低剂量钙离子拮抗剂为基础的联合方案治疗高血压的随机临床研究阶段报告-1［J］. 中国循证心血管医学杂志, 2008, 1(1):24-27.

［9］ Pedrinelli R, Dell’Omo G, Di Bello V, et al. Low-grade inflammation and microalbuminuria in hypertension［J］. Arterioseler Thromb Vasc Biol, 2004, 24(12):2414-2419.

［10］江国强,赵连友,李宏伟,等. 一氧化氮与高血压病患者病情的关系［J］. 实用心脑肺血管病杂志, 1998, 6(2):6-7.

［11］Fukuzawa J, Haneda T, Kikuchi K. Arginine vasopressin increases the rate of proteinsynthesis in isolated perfused adult rat heart via the V1 receptor［J］. Mol Cell Biochem, 1999, 195(2):93-98.

［12］陆小龙,赵连友,郑强荪,等. 拉西地平对AVP诱导的大鼠心脏成纤维细胞增值的影响及其与ERK1/2的关系［J］. 心脏杂志, 2008, 20(1):132-135.

［13］Berger ED, Bader BD, Ebert C, et al. Reduction of proteinuria;combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition［J］. J Hypertens, 2002, 20(4):73-79.

备注/Memo

备注/Memo:
收稿日期：2009-3-2.基金项目：国家十一五科技支撑计划子课题项目资助(2006BAI01A03) 通讯作者：赵连友，教授，主要从事高血压发病的分子生物学机制及防治研究Email:zhaolyfmmu@yahoo.com.cn 作者简介：艾永飞，医师，硕士生Email:elfy0124@yahoo.cn
更新日期/Last Update: 2009-05-18